Long-term follow-up needed after bone marrow mononuclear cell therapy for limb ischemia
This article has no abstract so we have provided the first paragraph of the full text.
Therapeutic options for critical limb ischemia are limited, and patients are often unresponsive to drug therapy or unsuitable for percutaneous or surgical revascularization. Transplantation of bone marrow mononuclear cells has previously been shown to have short-term clinical benefits for these 'no option' patients. Miyamoto et al. report on an uncontrolled, unblinded pilot study of the long-term safety and efficacy of transplantation therapy in patients with thromboangiitis obliterans.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
